Rose, Generic Lovaza has been a problem for AMRN forever. Management has not found any viable solution to this problem. Maybe if AMRN were owned by BP they would have figured out a solution to this. Vascepa usage will not be optimized in the hands of John Thero, it may be optimized once it is in the hands of the "right" BP. That always was and will continue to be the best way for Vascepa sales to be optimized.
My guess is that the right BP would be more aggressive legally and would find a way for the FDA to step in to protect the US population from ineffective medications such as Lovaza. At least this will not be a problem for Vascepa in Europe.